Novo Nordisk plans to invest an estimated $1.85B US dollars in new production facilities in Clayton, NC. Voted to Carolina Parenting Inc. Magazine’s List of “Top 50 Family Friendly Companies” and Most Valuable Employer for Military® by CivilianJobs.com, the Diabetes Finished Products and Diabetes Active Pharmaceutical Ingredients manufacturing facilities in Clayton, North Carolina will soon employ nearly 1,400 members of the community in Johnston County near the Research Triangle.
Diabetes Finished Products (DFP)
DFP helps support Novo Nordisk as a leader in diabetes by providing a complete product portfolio of insulin and GLP-1 products and offers easy-to-use insulin delivery systems. DFP is the primary supplier of Novo Nordisk diabetes and obesity products for the US market and secondary supplier in certain other foreign markets.
Diabetes Active Pharmaceutical Ingredients (DAPI)
DAPI will support Novo Nordisk in production and engineering. The plant will provide the U.S. with sufficient API capacity for diabetes products and help create almost 700 new jobs for the area. The final design and cost of the DFP and DAPI production facilities will be presented to the company’s board of directors for approval in 2016. The facilities are expected to be operational during 2020.
In the Community
Outside of excellence in manufacturing, Novo Nordisk supports the Clayton community through a variety of projects, including sponsorship of JDRF and the American Diabetes Association chapters and participation in local projects with Backpack Buddies, United Way and Angel Tree.